Retatrutide Side Effects
Retatrutide causes predominantly gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) that are dose-dependent and mostly mild-to-moderate in severity, along with dose-dependent increases in heart rate that peak at 24 weeks then decline. 1
Common Side Effects
Gastrointestinal Effects (Most Frequent)
The most commonly reported adverse events with retatrutide are gastrointestinal in nature 2, 1, 3:
- Nausea
- Vomiting
- Diarrhea
- Constipation
These GI effects are dose-related and occur in approximately 35% of patients receiving retatrutide (ranging from 13% at the 0.5 mg dose to 50% at the 8 mg fast escalation dose) 3. The severity is typically mild to moderate 1.
Important mitigation strategy: Starting with a lower initial dose (2 mg vs 4 mg) partially reduces the severity and frequency of gastrointestinal side effects 1.
Cardiovascular Effects
- Elevated heart rate: Dose-dependent increases that peak at 24 weeks and subsequently decline 1
- Injection site reactions 2
Metabolic Effects
- Hypoglycemia (particularly relevant in patients with type 2 diabetes) 3
Serious Safety Considerations
While no major safety concerns have been identified in phase 2 trials 4, retatrutide belongs to the incretin-based therapy class and shares theoretical risks with similar agents:
Theoretical Risks (Based on Drug Class)
Given retatrutide's mechanism as a GLP-1/GIP/glucagon receptor agonist, clinicians should monitor for class-related concerns seen with similar medications 5:
- Pancreatitis: Has been reported with GLP-1 agonists in clinical trials, though causality not established. Discontinue if pancreatitis is suspected.
- Acute kidney injury: Use caution when initiating or escalating doses in patients with kidney disease
- Cholelithiasis and gallstone-related complications
- Severe gastrointestinal disorders: Including severe constipation, small bowel obstruction, or ileus
- Thyroid C-cell tumors: Black box warning for GLP-1 agonists based on rodent studies; human relevance not determined
Safety Profile Summary
No severe hypoglycemia and no deaths occurred during phase 2 trials 3. The overall safety profile is consistent with GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists 3.
Clinical Monitoring Recommendations
- Monitor for gastrointestinal symptoms, particularly during dose escalation
- Track heart rate, especially during the first 24 weeks
- Monitor for delayed absorption of oral medications with narrow therapeutic index (e.g., warfarin)
- For patients on oral hormonal contraception: advise use of non-oral contraception method for 4 weeks after initiation and dose escalations (based on class effect) 5
- Assess kidney function when initiating or increasing doses
- Discontinue immediately if pancreatitis is suspected
Dose-Dependent Pattern
Higher doses (8-12 mg) produce greater weight loss but also higher rates of gastrointestinal side effects 1, 6. The 12 mg dose achieved the most significant weight reduction (24.2% at 48 weeks) but requires careful titration starting at 2 mg to optimize tolerability 1.